Company Overview
WHO WE ARE
ABOUT SDS OPTIC
We are an interdisciplinary team of scientists and business experts. We effectively merge optoelectronics with molecular biology, immunochemistry and biomedical engineering.
Our goal is to increase cancer survival rate by 30% by 2023. We want to achieve this by creating and developing advanced technologies for less invasive, real-time diagnostics.
management team
Knowledge and experience
We connect competences from the world of business and science. Experience and knowledge gained in international organizations allow us to effectively develop and commercialize the most innovative technological projects.
OUR TECHNOLOGY
We create, develop and plan to commercialise innovative diagnostic and monitoring devices to support the work of medical staff worldwide.
Find out more about the inPROBE technology and follow the latest achievments of our R&D department.
DEVELOPMENT STRATEGY & VISION
We have clear and well-defined goal.
Our vision is to increase the urvival rates for cancer and other chronic diseases to 30% by 2030, and co-create the future of disruptive healthcare technologies.
Discover our development strategy and find out more about our vision.
OUR MARKET
The cancer diagnostics market is estimated to reach over USD 311 billion by 2027.
In 2019, 7.5 million HER2 tests with a total value of more than USD 4 million were performed globally.
We are well prepared for the future commercialisation of our technology.
THEY TRUST US
Partners
management
Leadership Team
Our priority is an optimal structure of a leadership team, oriented towards the achievement of strategic goals and milestones.
Our leadership team combines scientific, technological, engineering, business, financial and operational competencies.
Marcin Staniszewski, MSc Eng.
Scientist | Engineer | Shareholder | CEO at SDS Optic
Supervises and coordinates photonics and biomedical engineering works.
Marcin Staniszewski, MSc Eng.
Co-founder, shareholder (indirectly via SDS Optonic Sp. z o.o. as its majority shareholder), Chief Technology Officer and CEO at SDS Optic S.A.
Supervises and coordinates photonics and medical bioengineering works.
Graduate of the University of Akron OH, USA (MSc Eng.), experienced scientist and technical engineer with managerial experience, works on innovative technologies with a civilisational influence on the society and economy.
He has many years of experience as a technologist in R&D departments in American technological companies. He participated in the research program in cooperation with NASA – Glenn Research Center (Cleveland, OH, USA), working with technologies used in the aviation and space industry. Member of the Polish-American Business Center in Boston, USA.
Magdalena Staniszewska, PhD, DSc
Professor KUL | Scientist | Shareholder | Chief Scientific Officer at SDS Optic SA
Supervises and coordinates molecular biology, immunochemistry and genetic engineering programs.
dr hab. n. med. Magdalena Staniszewska
Professor at the Catholic University of Lublin (KUL), Scientist | Project Leader | Shareholder | Chief Scientific Officer at SDS Optic SA.
Supervises and coordinates molecular biology, immunochemistry and genetic engineering programs.
Graduate of the Wrocław University of Science and Technology (MSc Eng.), specialisation: molecular biology and biocatalysis; PhD in biology, specialisation: immunochemistry at the Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences, and PhD in medicine, specialisation: biochemistry. Postdoctoral internship at the Case Western Reserve University (Cleveland, OH, USA). For many years engaged with Harvard Medical School (Boston, MA, USA).
Expert in eye diseases associated with diabetes, ageing and genetically determined disorders. Experienced initiator and leader of interdisciplinary scientific projects aimed at exploring mechanisms of diseases and in creating new therapeutic and diagnostic strategies of applied nature.
Mateusz Sagan, MBA
Economist | Manager | Shareholder | COO, CBO | CEO at the SPE: FiBioMed Sp. z o.o.
Supervises and coordinates operational, business, financial, project management and investment relations.
Mateusz Sagan, MBA
Shareholder, SVP / Chief Operating and Business Officer at SDS Optic S.A., CEO at the special purpose company FiBioMed Sp. z o.o.
Supervises and coordinates operational, business, financial, project management and investment relations.
Graduate of MBA studies at the University of Central Lancashire Preston (Great Britain). Expert in innovative research and development project management, more than 20 years of experience in the international corporate environment, including family companies and technological startups worldwide. Mentor of acceleration programmes (e.g. MIT EF CEE). Member of the Board of Directors at the Interim Managers Association in Poland and Member of the Board of the Lublin Medicine – Medical and Wellness Cluster.
advice and control
Supervisory Board
Krzysztof Klimkowski
Head of the Supervisory Board
Krzysztof Klimkowski
Member of the Supervisory Board
Lawyer and owner of the law firm Krzysztof Klimkowski Kancelaria Adwokacka. Graduate of the Faculty of Law and Administration at the Maria Curie-Sklodowska University in Lublin. Specialises in providing comprehensive legal aid for national and foreign entities in matters connected with business activities. Member of the European Association of Lawyers AEA-EAL and active participant in national and foreign conferences organised by the Association.
Damian Serafin
Member of the Supervisory Board
Damian Serafin
Member of the Supervisory Board
Co-owner and Managing Director at DEXPRO S.C. MSc in Economics, Originator and Co-owner of the factory with furniture accessories (co-founder, CEO at DEXPRO), Owner of DS Business Consulting, Vice-President of the sports foundation Perfect Runner, former long-standing manager of building structures and sales development in CEE at Hettich in Germany.
Andrzej Kołodziejczyk
Member of the Supervisory Board
Andrzej Kołodziejczyk
Member of the Supervisory Board
Investment Project Manager at the Polish Entrepreneurship Foundation.
Responsible for capital investments by the Pomeranus Seed fund and supervision over companies, expert in corporate banking, graduate of post-graduate studies in investment banking.
dr inż. Adam Piotrowski
Member of the Supervisory Board
Adam Piotrowski, PhD Eng.
Member of the Supervisory Board
PhD Eng. in technical sciences at the Military Technical Academy, for nearly 20 years engaged at Vigo Photonics S.A. (Warsaw Stock Exchange: VGO), a global leader in photonic IR detector technologies and technological leader in photonics (optic fibre technologies). CEO at Vigo System S.A. for more than 6 years, CEO of the Association of Employers at the Polish Technological Platform on Photonics since May 2017. Member of the Supervisory Board at the investment fund VIGO WE INNOVATION and Creotech Instruments S.A. Since April 2021, Member of the Board of the European Photonics Industry Consortium (EPIC).
Szymon Ruta
Member of the Supervisory Board
Szymon Ruta
Member of the Supervisory Board
Graduate of MBA studies at the University of Warsaw. For more than 5 years, Member of the Board and Financial Director at Scope Fluidics (NC: SCPFL), former long-standing Managing Director at MS TFI S.A. Former Member of Supervisory Boards at portfolio companies MARS Closed-End Investment Fund and Azoty Group Chemical Plants POLICE. Manager with more than 15 years of experience in projects connected with fusion, takeovers, investments and restructuring. Former manager of a EUR 125 million fund. Currently, Member of the Board at Bacteromic Sp. z o.o.
dr Marcin Wawrzynowicz
Member of the Supervisory Board
Marcin Wawrzynowicz, PhD
Member of the Supervisory Board
Appointed as a Member of the Supervisory Board in a personal capacity.
PhD in arts in the field of art of music at the Karol Szymanowski Academy of Music in Katowice. For 16 years engaged in artistic and educational work as academic teacher. Since 2020, Deputy Dean at the Faculty of Jazz at the Academy of Applied Sciences in Nysa.
Statement of absence of conflict of interest
We hereby solemnly declare that the Members of the Supervisory Board and persons holding management positions at SDS Optic S.A. have the required knowledge, skills and experience, and they guarantee the due execution of their duties. Each of the appointed persons is characterised by a good reputation and credibility, as well as an absence of conflict of interest.
We hereby solemnly declare that the Members of the Supervisory Board and persons holding management positions at SDS Optic S.A. have the required knowledge, skills and experience, and they guarantee the due execution of their duties. Each of the appointed persons is characterised by a good reputation and credibility, as well as an absence of conflict of interest.
SDS OPTIC S.A.
Shareholder Structure
SDS Optonic Sp. z o.o. (Marcin Staniszewski & private investors)
Polish Entrepreneurs Foundation
INNOventore ASI Sp. z o. o.
Marcin Staniszewski (prywatnie)
Magdalena Staniszewska, PhD, DSc prof. KUL
Other shareholders < 5%
| No | SHAREHOLDERS | NUMBER OF SHARES | % OF SHARES | NUMBER OF VOTES | % OF VOTES |
| 1 | SDS Optonic Sp. z o.o. (Marcin Staniszewski & private investors) | 2 358 260 | 40,44% | 2 358 260 | 40,44% |
| 2 | Polish Entrepreneurs Foundation | 519 240 | 8,91% | 519 240 | 8,91% |
| 3 | INNOventure ASI Sp. z o.o. | 483 750 | 8,30% | 483 750 | 8,30% |
| 4 | Marcin Staniszewski (priv) | 15 000 | 0,26% | 15 000 | 0,26% |
| 5 | Magdalena Staniszewska, PhD, DSc prof. KUL | 105 900 | 1,81% | 105 900 | 1,81% |
| 6 | Other shareholders < 5% | 2 348 700 | 40,28% | 2 348 700 | 40,28% |
| SUMMARY | 5 830 850 | 100% | 5 830 850 | 100% |
Pursuant to the Articles of Association, the Company share capital is PLN 5 830 850 divided into 5 830 850 ordinary bearer series A, B, C, D, E and F shares.
Series A, B and C shares were issued as registered shares and became bearer shares, pursuant to Resolution No. 2 of the Company Board, 25 August 2021, which was passed following shareholder applications for the conversion of series A, B and C shares from registered to bearer shares, pursuant to Article 8 section 5 of the Articles of Association. Series D, E and F shares have been bearer shares since the issue date.
| SERIES OF SHARES | NUMBER OF SHARES | NUMBER OF VOTES | TYPE OF SHARES | NOMINAL VALUE | ISSUE PRICE | DATE OF SHARE ISSUE RESOLUTION | DATE OF REGISTRATION IN THE KRS |
| A | 3.843.000 | 3.843.000 | ordinary bearer | 1,00zł | 1,00zł | 10.01.2019 r. | 17.05.2019 r. |
| B | 83.250 | 83.250 | ordinary bearer | 1,00zł | 1,20zł | 22.07.2019 r. | 10.09.2019 r. |
| C | 300.000 | 300.000 | ordinary bearer | 1,00zł | 1,00zł | 22.04.2021 r. | 25.05.2021 r. |
| D | 1.100.000 | 1.100.000 | ordinary bearer | 1,00zł | 10,00zł | 25.05.2021 r. | 15.07.2021 r. |
| E | 54.600 | 54.600 | ordinary bearer | 1,00zł | 1,00zł | 25.05.2021 r. | – |
| F | 450.000 | 450.000 | ordinary bearer | 1,00zł | 13,00zł | 25.01.2023r. | 23.02.2023 r. |
Information on personal, property and organisational relationships between:
1. The Issuer and the members of the management and supervisory bodies of the Issuer:
The personal, organisational and property relationships between the Issuer’s Company and members of the management and supervisory bodies of the Issuer:
- Marcin Staniszewski – CEO, is at the same time a shareholder and CEO at SDS Optonic Sp. z o.o., a significant Issuer shareholder with 2 358 260 shares of the Issuer, accounting for 40,44% of shares in the Company’s share capital and the same percentage of votes at the Shareholder General Meeting of the Issuer.
- Marcin Staniszewski – CEO of the SDS Optic S.A. is at the same time a shareholder of the Company, is holder of 15,000 shares of the Issuer, accounting for 0.26% of shares in the Company’s share capital and the same percentage of votes at the Shareholder General Meeting of the Issuer.
- Damian Serafin – since 20 July 2022 Member of the Supervisory Board, is at the same time a shareholder of the Company, is holder of 20,792 shares of the Issuer, accounting for 0.36% of shares in the Company’s share capital and the same percentage of votes at the Shareholder General Meeting of the Issuer.
2. The Issuer or members of the management and supervisory bodies of the Issuer and significant shareholders of the Issuer:
The personal, organisational and property relationships between the Issuer’s Company or members of the management and supervisory bodies of the Issuer and significant shareholders of the Issuer:
- Magdalena Staniszewska – holder of 105 900 shares of the Issuer, accounting for 1.81% of shares in the Company’s share capital and the same percentage of votes at the Shareholder General Meeting of the Issuer; wife of the CEO – Mr Marcin Staniszewski.
Other Members of the Supervisory Board of the Issuer are not related to the shareholders, holding shares representing at least 5% of the total number of votes at the Shareholder General Meeting.
Information on Dividend
The Ordinary General Meeting of Shareholders is entitled to decide on the distribution of profits and the payment of dividends, as well as whether and how much dividend will be paid. All shares of the Company have the right to participate in dividend payments.
The decision on the distribution of profits is taken as a resolution at the Ordinary General Meeting of Shareholders, and passed following the end of each financial year.
Any future decisions on the payment of dividends or the appropriation of profits entirely or partially to the Company reserves will be at the discretion of the General Meeting, subject to the provisions of applicable law.
